Evidence map›Paper›PMID 31456212›Full record

ReviewNeurology and therapy2019

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer.

Jeremy K Cutsforth-Gregory, Phillip A Low

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Don't miss the prodrome: neurogenic orthostatic hypotension as a window into multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  3. Review
  4. Redefining Non-Motor Symptoms in Parkinson's Disease.Journal of personalized medicine · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Effect of strength training on orthostatic hypotension in Parkinson's disease-a pilot study.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Autonomic Dysfunction in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jeremy K Cutsforth-GregoryDepartment of Neurology, Mayo Clinic, Rochester, MN, USA. CutsforthGregory.Jeremy@mayo.edu.
Phillip A LowDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Studies on Diagnosis, Pathophysiology, and Treatment of Autonomic Failure in MSAP01NS044233 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOW, PHILLIP A · 2003 to 2014
$12.4M
Training CoreU54NS065736 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KAUFMANN, HORACIO · 2009 to 2018
$11.6M
Synucleinopathies – Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic ApproachR01NS092625 · NINDS · MAYO CLINIC ROCHESTER · PI SINGER, WOLFGANG, VEMURI, PRASHANTHI · 2015 to 2025
$6.6M
Phase 1 Study of Autologous Mesenchymal Stem Cell in Multiple System AtrophyR01FD004789 · FDA · MAYO CLINIC ROCHESTER · PI LOW, PHILLIP A · 2014 to 2016
$600k
ELECTRODE ARRAYS BASED ON THIN FILM TECHNOLOGYN01NS032352 · NINDS · STANFORD UNIVERSITY · PI WHITE, ROBERT L · 1985 to 1985
–
FDA HHS R01 FD004789NCATS NIH HHS UL1 TR000135NIH HHS NS 32352NIH HHS NS44233NIH HHS NS92625NIH HHS U54 NS065736NINDS NIH HHS N01 NS032352NINDS NIH HHS P01 NS044233NINDS NIH HHS R01 NS092625NINDS NIH HHS U54 NS065736
6 · The paper itself

Abstract

Parkinson disease (PD) is associated with a variety of motor and non-motor clinical manifestations, including cardiovascular autonomic dysfunction. Neurogenic orthostatic hypotension (nOH) is a potentially serious manifestation of cardiovascular sympathetic failure that occurs in approximately 30% of patients with PD. Here we review the pathophysiology and effects of the condition as well as treatment considerations for patients with PD and nOH. Screening for nOH using orthostatic symptom questionnaires, orthostatic blood pressure measurements, and specialized autonomic testing is beneficial for the identification of symptomatic and asymptomatic cases because cardiac sympathetic denervation and nOH can occur even at early (premotor) stages of PD. Symptoms of nOH, such as orthostatic lightheadedness, in patients with PD, have been shown to adversely affect patient safety (with increased risk of falls) and quality of life and should prompt treatment with non-pharmacologic and, occasionally, pharmacologic measures. Patients with nOH are also at increased risk of supine hypertension, which requires balancing various management strategies.

fundingLundbeck (Deerfield, IL).

Indexed as

Non-motor symptoms of Parkinson diseaseOrthostatic hypotensionScreeningSupine hypertensionTreatment

Identifiers

PMID31456212
PMCPMC6946781
OpenAlexW2970968734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.